Prime Medicine Reports FY25 Results, $191M Cash Runway into 2027

• Prime Medicine on track to file IND for Wilson Disease and CTA for AATD programs in 2026 • Initial clinical data expected in 2027 • Ongoing engagement with FDA for PM359 in CGD • Plan to submit BLA following final alignment • Cash, cash equivalents, investments, and restricted cash of $191M, providing runway into 2027